Blackbird Bioventures

Advisory board member and co-founder and General Partner of Hatteras Venture Partners, which he helped establish in 2000. He has co-founded eight life sciences companies and been involved in over 90 life science investments. Holds a Master of Public Policy from Harvard.

CEO of Blackbird Laboratories and Managing Director of Blackbird BioVentures. Previously COO of Scripps Research and its drug discovery division Calibr, which he helped launch and run for a decade. Holds a PhD in Chemistry from Columbia University.

Venture Partner responsible for opportunity identification, scientific development, and NewCo formation. Previously Head of Muscle Biology at ReNAgade Therapeutics and held roles at Fulcrum Therapeutics, and consulted for Third Rock Ventures. Holds a PhD in Human Physiology from Boston University.

Venture Partner responsible for project management, NewCo leadership, company creation, and scientific diligence. Previously at Foresite Capital, Ophthotech (now Iveric Bio), and the Critical Path Institute; began his career as a medicinal chemist at Merck. Holds a PhD in Organic Chemistry from Harvard University.

Venture Partner responsible for new company creation, scientific diligence, and translational projects. Previously at Foresite Capital and an Executive Director at Merck Research Laboratories in Translational Medicine. Holds an MD from Cornell and a PhD in Genetics from Rockefeller University.

Venture Partner focused on creating new therapeutics ventures. Co-founded TriBiotica LLC, an oncology company, where he served as President and co-invented its core technology. Earlier roles at CytoCure and ACGT. Holds a Bachelor's in Biology from the University of Wisconsin-Madison.

Venture Partner who builds biotechnology companies. Founder and former CEO of New Equilibrium Biosciences, which targets intrinsically disordered proteins via a computational-experimental platform; previously worked at XtalPi. Holds a PhD in Computational Biology from the University of Pittsburgh and Carnegie Mellon University.

Advisory and steering board member and Partner at Stepstone Group, leading sourcing and diligence across fund, direct, and secondary investments. Previously at Domain Associates and Esprit Pharma. Holds an MBA from Darden.

Advisory board member and Partner at Bain Capital Life Sciences, which he joined in 2018. Previously a Partner at McKinsey & Company in the Biopharmaceutical and Medical Products Practice. Holds an MD from Johns Hopkins.

Office Manager supporting operational and administrative functions. Previously held operations roles focused on process improvement and project coordination. Holds an undergraduate degree in Computer Science from Bowie State University.

Senior Director of Molecular Discovery overseeing research programs and collaborations. Previously a Principal Scientist at Hansoh Bio and a medicinal chemist at Constellation Pharmaceuticals. Holds a PhD in Chemistry from UC Irvine.

Director of Lab Operations managing planning and execution for the opening of Blackbird BioHub. With 15+ years in drug development, she is a co-inventor of Cedazuridine and previously led laboratory operations at Barinthus Biopharmaceutics.

Entrepreneur in Residence with over 20 years of experience in company formation and life sciences. Founded or helped build nine startups, was a BCG consultant, and served as Institute Professor of Translational Engineering at the University of Maryland. Most recently CSO at Cartesian Therapeutics.

Advisory board member and Global Head of AbbVie Ventures, a trained geneticist, neurobiologist, and biochemist with experience in company creation, venture investing, and external innovation across global biotech hubs.

Steering board member and Senior Advisor to the President and Executive Director of Johns Hopkins Technology Ventures, where she has reshaped commercialization efforts. A seasoned life sciences entrepreneur and investor who co-founded UpSurge. Holds an MBA from NYU Stern.

Advisory board member and Partner on Canaan's healthcare investment team, with board roles at several therapeutics companies. Earned her PhD in Cellular and Molecular Physiology from Yale University.

Advisory board member, Partner, and Executive Chair of the 4:59 Initiative at 5AM Ventures. Previously VP of Corporate Development & Strategy at Relay Therapeutics and helped found Blueprint Medicines and Editas Medicine at Third Rock Ventures. Holds a PhD from Columbia University.

Chief Business Officer overseeing business operations, investment strategy, and company formation. Previously a founding team member and Head of Corporate Development at Shoreline Biosciences, and earlier worked at Scripps/Calibr and Flagship Pioneering. Holds a PhD in Molecular Medicine from the University of Maryland, Baltimore.

Head of Finance and Operations overseeing finance and accounting. Previously built the finance function of an edtech startup and directed financial operations at the O'Neill Institute at Georgetown Law. Holds an MBA from Virginia Tech.

Associate Director of Ventures supporting early drug discovery programs and external partnerships. Earned her PhD in Molecular Biophysics at the Johns Hopkins School of Medicine, researching ribosome quality control and mRNA decay.

Advisory board member and Managing Director of Boehringer Ingelheim Venture Fund USA, investing in early-stage biotech therapeutics and platform technologies. Previously held leadership roles at Boehringer Ingelheim Pharmaceuticals. Holds a PhD in Neuropharmacology.

Entrepreneur in Residence and founding CEO of Aletira Therapeutics, which builds gene therapies using alternative splicing biology. Founded and led Avidea Technologies through its acquisition by Vaccitech (now Barinthus Biotherapeutics), where he became CSO. Holds an MD from Johns Hopkins and a PhD in Biomedical Engineering from Oxford.

Steering board member and Chief Enterprise and Economic Development Officer at the University of Maryland, Baltimore, overseeing research, philanthropy, and entrepreneurial efforts. President of the UMB BioPark. Holds an MBA from Columbia Business School.

Advisory board member and Partner at RA Capital Management leading early-stage private investments and new company development. Previously co-led SV Health Investors' US Biotech practice and was a Venture Partner at Atlas Venture. Holds an MD and MBA.

Chief of Staff partnering with leadership on strategy and partnerships for early-stage life science companies. Previously a Biologics Scientist at the Tri-Institutional Therapeutics Discovery Institute. Holds a PhD in Genetics from Albert Einstein College of Medicine.

Steering board member and Managing Director and Founder of rDNA.ai, a biopharma consulting and AI-driven database firm. Previously founded Bioscience Advisors and Recombinant Capital. Holds an MBA from Stanford University.

Steering board member and Co-CEO of Brown Advisory, an investment management and strategic advisory firm. He served as CEO of Brown Advisory from 1998 until the Co-CEO transition in 2025. Holds a JD from the University of Virginia.

Steering board member and Managing Partner at Digitalis Ventures, which invests in solutions to complex health problems. Founder and former CEO of TARA Biosystems. Holds a PhD in Biochemical Engineering from University College London.

Advisory board member and Managing Director at Cure Ventures with three decades in the life sciences sector. Previously Managing Member and President of Omega Funds and founder of MVM's US operations. Holds an MBA from Harvard Business School.

Advisory board member and Partner at Illumina Ventures investing in early-stage biotech combining genomics, AI, and high-throughput biology. Previously held senior roles at Genentech, Johnson & Johnson, and Merck. Holds a PhD in Biochemistry and an MBA.

Steering board member and President of Point Field Partners, the family office for Baltimore Ravens owner Steve Bisciotti. Previously at Brown Advisory and Venable LLP, and began his career at McKinsey. A CFA charterholder with a JD from the University of Virginia.

Steering board member and President of the Baltimore Ravens, overseeing the organization's business operations. Previously at Monumental Sports & Entertainment and the Cleveland Browns. Holds a JD from Harvard Law School.

Entrepreneur in Residence specializing in computational and statistical methods for non-invasive diagnostics and liquid biopsies. Completed his PhD in biostatistics at Johns Hopkins and cofounded Delfi Diagnostics, where he worked on cell-free DNA fragmentomics and machine learning for cancer detection.

Advisory board member and Partner at Foresite Capital and CSO, Therapeutics at Foresite Labs. Previously held leadership roles at the Calibr-Skaggs Institute. Holds a PhD in Chemical Biology from Scripps Research.

Director of Research Programs and Operations supporting early drug discovery and external partnerships. Previously a Research Scientist at NIH's NCATS and a Senior Research Scientist at Reaction Biology Corporation. Holds a PhD in Biochemistry and Molecular Biology from Rutgers University.